Prostate Cancer Care Disparity Analysis Project (ProGAP)
Evaluating the Worldwide Landscape of Prostate Cancer Management
This international cross-sectional study seeks to evaluate global disparities in prostate cancer management by conducting a thorough comparison of key elements across countries categorized as low-income, lower-middle-income, upper-middle-income, and high-income.
The primary question it addresses is: Are the standards of care for prostate cancer uniformly applied across different geographic regions worldwide? To achieve this, we will recruit physicians specializing in the diagnosis and treatment of prostate cancer from a diverse array of countries within these income classifications. Participants will complete a 17-question online survey.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Prostate cancer stands as one of the most common cancers among men worldwide, with outcomes and care quality significantly varying due to a multitude of factors including geographic location, healthcare infrastructure, socioeconomic status, and clinical practices. The ProGAP project is conceived to delve into these variations, providing a detailed examination of the global landscape of prostate cancer care.
Objectives:
- To systematically gather and analyze data on current diagnostic methods, treatment modalities, and management practices for prostate cancer from a wide range of countries and healthcare settings.
- To identify and quantify disparities in access to and availability of standard care, novel treatments, and supportive services for patients with prostate cancer.
- To evaluate the adherence levels to both international and national guidelines in prostate cancer treatment across diverse healthcare systems.
Methods:
The ProGAP survey will be distributed internationally to healthcare professionals, including urologists, uro-oncologists, medical oncologists, and radiation oncologists, who are actively involved in prostate cancer care. The survey will comprehensively cover demographic details, clinical practice environment, patient demographics and stages managed, guideline adherence, availability and use of diagnostic and treatment options, and multidisciplinary care approaches. A survey and a consent form will be sent to study participants in addition to written information about the study. Completing surveys will take 10-12 minutes. Participants will complete a 17-question online survey. The first part of the form includes questions about demographics and hospital characteristics. The second part contains questions about prostate cancer diagnosis, treatment, and management practices. Participation in this study is entirely voluntary and anonymous. Neither sensitive personal data nor contact information will be collected during the research. This research does not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors, and the investigators declare that they do not have any conflict of interest with the work.
Data Analysis Plan:
Statistical analyses will employ both descriptive and inferential statistics to interpret the survey data. Comparative analyses will be conducted to uncover disparities across different regions and healthcare settings. Advanced statistical methods, such as regression analysis, may be utilized to explore factors associated with variations in care practices and outcomes.
Expected Impact:
By elucidating the disparities in prostate cancer care worldwide, ProGAP aims to stimulate policy changes, guide improvements in clinical practice, and foster international collaborations to enhance the quality of care and outcomes for patients with prostate cancer globally. Insights gained from this project are anticipated to inform stakeholders, including healthcare providers, policymakers, and patient advocacy groups, about critical areas for intervention and improvement.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Yüksel Ürün
- Phone Number: 800-555-5555
- Email: yukselurun@gmail.com
Study Contact Backup
- Name: Satı Coşkun Yazgan
- Phone Number: +905304517798 800-555-5555
- Email: coskunyazgann491@gmail.com
Study Locations
-
-
-
Ankara, Turkey, 06590
- Recruiting
- Ankara University Faculty of Medicine
-
Contact:
- Yüksel Ürün, M.D.
- Phone Number: +905304517798
- Email: yukselurun@gmail.com
-
Contact:
- Satı Coşkun Yazgan, M.D.
- Phone Number: +903125883061
- Email: coskunyazgann491@gmail.com
-
Sub-Investigator:
- Satı Coşkun Yazgan, M.D.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
Urologists, Uro-oncologists, Medical oncologists, Radiation oncologists
Exclusion Criteria:
Non-clinical healthcare professionals Healthcare professionals not directly involved in the care of prostate cancer patients, Healthcare professionals with missing or incorrect email addresses
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Healthcare professionals for prostate cancer
Healthcare professionals actively engaged in prostate cancer treatment, including urologists, uro-oncologists, medical oncologists, and radiation oncologists
|
No Intervention: Observational Cohort
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Characterization of global disparities in prostate cancer diagnosis, treatment, and management practices
Time Frame: One month
|
Comparative analyses will be conducted using survey data to reveal disparities between different regions and healthcare settings.
The findings will be presented as percentages of respondents, with territorial and institutional differences thoroughly evaluated.
Participants will be categorized into three groups based on the World Bank's income classification: low and lower-middle, upper-middle, and high-income countries.
Descriptive statistics will be employed to compare demographic characteristics and clinical practices.
For categorical data analysis, the Pearson Chi-Square or Fisher's Exact test will be utilized, while ANOVA tests will be applied to independent variables.
A p-value of less than 0.05 will be considered statistically significant.
|
One month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Assessment of access to care, encompassing advanced diagnostic tools, treatment modalities, and patient support services; analysis of adherence to guidelines and its effect on treatment outcomes
Time Frame: One month
|
Identifying the percentage of healthcare professionals across various geographic regions who have access to diagnostic and treatment methods that align with established guidelines, and evaluating the impact of these methods on treatment outcomes.
The findings will be presented as percentages of respondents, with territorial and institutional differences thoroughly examined.
|
One month
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Yüksel Ürün, Ankara University
- Study Director: Deborah Mukherji, Clemenceau Medical Center Hospital Dubai
- Study Director: Mohammed Shahait, Al Zahra Hospital Dubai
- Study Director: Luis Castelo Branco, IOSI Oncologist Institute of Southern Switzerland
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ANKARA-UNIVERSITY-YURUN-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.